Contact
Header_1077x260px_About_Profil.jpg

GLP-1 based drugs: Could Elon Musk’s weight loss weapon help us, too?

Profil's scientific publications in 2023 - an overview

A novel long-acting Amylin analogue for the management of obesity

CTR 536/2014: First approvals and our experience with CTIS (Part 3)

Corporate Social Responsibility in Clinical Trials

Unique Device Identifier, UDI, examplified by Profil’s class IIb medical device “ClampArt” (Part II)

Unique Device Identifier, UDI, examplified by Profil’s class IIb medical device “ClampArt” (Part I)

IDF School of Diabetes: Biosimilar Insulins - Complimentary online course

CTR 536/2014: CTIS - the single entry point for submitting clinical trials in the EU (Part 2)

CTR 536/2014: Where do we come from and where do we go? (Part I)